Lai N-s, Wu D-g, Fang X-g, Lin Y-c, Chen S-s, Li Z-b, Xu S-s
Department of Neurosurgery, First Affiliated Hospital of Wannan Medical College, 2 West Zheshan Road, Wuhu City 241001, China.
Department of Neurosurgery, Wuxi Second Hospital Affiliated to Nanjing Medical University, 68 Zhongshan Road, Wuxi City 214001, China.
Br J Cancer. 2015 Mar 31;112(7):1241-6. doi: 10.1038/bjc.2015.91.
MicroRNA-210 (miR-210) is an oncogenic miRNA previously associated with prognosis in human gliomas, an incurable tumour type of the central nervous system. Here miR-210 was investigated as a potential serum biomarker in the diagnosis and prognosis of glioma.
Serum was immediately prepared from blood samples collected from patients with glioma grades I-IV at primary diagnosis (n=136) and healthy controls (n=50) from February 2007 to March 2014 in the Department of Neurosurgery of the First Affiliated Hospital of Wannan Medical College (Wuhu, China). Total RNA was isolated from serum. cDNA was synthesised with primers specific for miR-210 and miR-16-1 (internal control), and quantitative real-time RT-PCR was performed. Results were statistically analysed to determine the role of miR-210 in the diagnosis and prognosis of human glioma patients.
An approximately seven-fold increase in miR-210 expression was detected in serum samples from glioblastoma patients relative to healthy controls. A threshold expression value (2.259) was chosen from receiver operator characteristic curves (ROC), and the low and high miR-210 expression groups were analysed by multivariate Cox proportional hazard regression and Kaplan-Meier analyses. Results revealed an association of high serum miR-210 expression with tumour grade and poor patient outcome (P-values <0.001).
Serum miR-210 is a promising diagnostic and prognostic biomarker that can be detected in the peripheral blood of patients with glioma.
微小RNA-210（miR-210）是一种致癌性微小RNA，先前已被证明与人类胶质瘤（一种中枢神经系统的不治之症肿瘤类型）的预后相关。本文研究miR-210作为胶质瘤诊断和预后的潜在血清生物标志物。
2007年2月至2014年3月期间，从皖南医学院第一附属医院神经外科收集了原发性诊断为I-IV级胶质瘤患者（n=136）和健康对照者（n=50）的血液样本，并立即制备血清。从血清中分离总RNA。使用针对miR-210和miR-16-1（内对照）的特异性引物合成cDNA，并进行定量实时逆转录PCR。对结果进行统计学分析，以确定miR-210在人类胶质瘤患者诊断和预后中的作用。
相对于健康对照者，胶质母细胞瘤患者血清样本中miR-210表达增加了约7倍。从受试者工作特征曲线（ROC）中选择一个阈值表达值（2.259），并通过多变量Cox比例风险回归和Kaplan-Meier分析对低和高miR-210表达组进行分析。结果显示血清miR-210高表达与肿瘤分级和患者预后不良相关（P值<0.001）。
血清miR-210是一种有前景的诊断和预后生物标志物，可在胶质瘤患者外周血中检测到。
